Core Points - Kiora Pharmaceuticals has been granted a U.S. patent (US Patent No. 12,364,680) for KIO-104, which covers treatment for various ocular diseases, including ocular inflammation, uveitis, and age-related macular degeneration, extending market exclusivity until 2043 [1][2] - The patent enhances Kiora's intellectual property strategy by protecting KIO-104's proprietary structure, delivery methods, and therapeutic applications, positioning it as a significant alternative to existing steroid treatments [2] - KIO-104 is currently undergoing a Phase 2 clinical trial (KLARITY study) to evaluate its efficacy in treating inflammatory retinal diseases, with initial results expected to guide further development [3] Company Overview - Kiora Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapies for retinal diseases, utilizing innovative small molecules to address vision loss [5] - KIO-104 is a next-generation, non-steroidal, immuno-modulatory small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH), aimed at treating retinal inflammation [5] - The company is also developing KIO-301 for retinitis pigmentosa and other retinal degenerative diseases, which has the potential to restore vision in affected patients [5]

– Video webcast now available on-demand  HOUSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that Walter Klemp, Founder, President, CEO and Chairman of Moleculin, participated in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference. As part of the segment, Mr. Klemp dove deeper into h ...

– Video webcast now available on-demand LA JOLLA, CA, July 22, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced Marc Hertz, PhD, President, Chief Executive Officer and Director of GRI BIO, participated in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference. As part ...

– Video webcast now available on-demand Carlsbad, CA, July 22, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced JD Finley Chief Executive Officer of Palisade Bio, participated in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference. As part ...

Video webcast now available on-demand ISELIN, N.J., July 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that Bob Jahr, newly appointed Chief Executive Officer, participated in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference. As part of the event, Mr. Jahr dove deeper into what brought him to Outlook Therapeutics, h ...

NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action. Investors have until August 25, 2025, to as ...

MIAMI, FL, July 22, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that the company will be participating in one-on-one meetings and a fireside chat presentation with investors at the 2025 BTIG Virtual Biotech Conference taking place from July 29-30, 2025. About Veru Inc.Veru is a late clinical stage biopharmaceutical company focused o ...

NEW YORK, July 22, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharma innovator, today announced a CRADA (Cooperative Research and Development Agreement) with the U.S. Department of Veterans Affairs and Foundation for Atlanta Veterans Education and Research (FAVER) to evaluate GDNF (glial cell-derived neurotrophic factor) as a novel metabolic therapy targeting obesity and hepatic steatosis (fatty liver disease).The study, conducted at the Atlanta VA Medical Center, will ...

NEW YORK, July 22, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharma innovator, today announced a CRADA (Cooperative Research and Development Agreement) with the U.S. Department of Veterans Affairs and Foundation for Atlanta Veterans Education and Research (FAVER) to evaluate GDNF (glial cell-derived neurotrophic factor) as a novel metabolic therapy targeting obesity and hepatic steatosis (fatty liver disease). The study, conducted at the Atlanta VA Medical Center, will ...

The Company will Host a Conference Call and Webcast on Thursday, August 7, 2025, at 8:30 AM ETCORAL GABLES, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its second quarter 2025 financial results after the market close on Wedne ...